塞曲司特联合孟鲁司特治疗支气管哮喘疗效观察

目的评价塞曲司特联合孟鲁司特治疗支气管哮喘的疗效。方法试验组15例，口服塞曲司特颗粒剂80mgqd加孟鲁司特10mg，qd疗程6周。对照组15例，口服孟鲁司特10mg，qd，疗程6周。结果两组于治疗后均有显著改善，但两组间无显著差异。结论塞曲司特治疗支气管哮喘的疗效已经肯定，但联合孟鲁司特治疗支气管哮喘疗效并未能够进一步加强。

Clinical efficacy of montelukast associated with seratrodast on asthma patients

Objective To evaluate the clinical efficacy of montelukast associated with Seratrodast on asthma patients. Methods A total of 60 patients with asthma were randomly divided into two groups ： seratrodast group （ group A） and montelukast group （ group B ）. 30 patients in group A were treated with seratrodast 80 mg,po,qd for 6wk, and 30 patients in group B were treated with montelukast 1 0 rag, po, qd for6wk. Results There was significant amelioration concerning the clinical efficacy rates and lung function efficacy rates, respectivdy, without serious cases in both groups and also no statistically significant difference between them （ P 〉 0. 05 ）. Conclusion Seratrodast is a new, safe, and effective drug in treating patients with asthma and possesses reliable efficacy and less adverse reaction similar to montelll kast. Montelukast associated with seratrodast can be used to treat asthma effectively.